Integrating Recent Advances into the Management of Relapsed/Refractory Multiple Myeloma: Bispecifics, ADCs and CELMoDs
A CME/MOC-Accredited Interactive Grand Rounds Series
Research To Practice (RTP) is pleased to offer hospitals and cancer centers throughout the United States the opportunity to participate in an interactive, live continuing education program. Each session in this regional series will feature a renowned clinical investigator delivering a didactic presentation, sharing steering committee treatment recommendations and engaging attendees through Q&A discussion.
What’s included:
- A 1-hour activity led in person by a member of our steering committee under the leadership of Neil Love, MD
- In-depth discussion of real-world cases, investigator responses, emerging data and ongoing trials
- Audience Q&A discussion
- No cost to your institution — fully provided by RTP
If you are interested in hosting a session at your organization, please email our Meetings Department at Meetings@ResearchToPractice.com or call (800) 233-6153.
Natalie S Callander
MD
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program
Sagar Lonial
MD, FACP, FASCO
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
Chair and Professor, Department of Hematology and Medical Oncology, Anne and Bernard Gray Family Chair in Cancer, Chief Medical Officer
Robert Z Orlowski
MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, Texas
Florence Maude Thomas Cancer Research Professor, Department of Lymphoma and Myeloma, Professor, Department of Experimental Therapeutics, Vice Chair, Myeloma Translational Research, Division of Cancer Medicine
Douglas W Sborov
MD, MS
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Professor of Medicine, Adjunct Associate Professor of Molecular Pharmaceutics and Biomedical Engineering, Craig and Marianne Mecham Endowed Chair in Hematological Oncology
These activities are supported by an educational grant from GSK.
Each 1-hour session will include 3 topic modules focused on recent advances in the management of relapsed/refractory multiple myeloma. Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Q&A Discussion
MODULE 1 — Bispecific Antibody Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)
MODULE 2 — Antibody-Drug Conjugates for R/R MM
MODULE 3 — Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) in the Treatment of R/R MM
Each session will conclude with a 5-minute Q&A segment.
Target Audience
These activities are intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
Learning Objectives
To be announced.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Steering Committee
Dr Callander has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Boards of Directors: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Stock Options/Stock — Public Companies: TG Therapeutics Inc. Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, DEM BioPharma, GSK, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neurogene Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma AG, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Sanofi. Dr Sborov — Advisory Committees: GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc, Sanofi; Consulting Agreements: Bristol Myers Squibb, GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Legend Biotech, Opna Bio, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: GSK, Karyopharm Therapeutics. Additional faculty to be announced.
Program Chair — Neil Love, MD, is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
These activities are supported by an educational grant from GSK.